Fibroscan for Assessment of Non Alcoholic Fatty Liver Disease in Type 2 Diabetic Patients in Tanta University Hospital

HANAN H. SOLIMAN, M.D., NASRAT M. AYAD, M.D.;; MOHAMMED I. GAMAL ELDIN, M.Sc., NOHA E. ESHEBA, M.D.;

doi:10.21608/mjcu.2018.62806

Fibroscan for Assessment of Non Alcoholic Fatty Liver Disease in Type 2 Diabetic Patients in Tanta University Hospital

Document Type : Original Article

Authors

The Department of Internal Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt

10.21608/mjcu.2018.62806

Abstract

Abstract
Background: Fibroscan has recently been investigated as a new technique in the assessment of fibrosis of the liver in many diseases.
Aim of Study: Was to evaluate the role of fibroscan in assessment of liver steatosis and fibrosis in patients with type 2 diabetes and NAFLD.
Patients and Methods: The study population consisted of 40 patients with type 2 diabetes and 20 patients with obesity as controls. Patients with type 2 diabetes were divided into two groups: Group IA patients with type 2 diabetes and obesity and group IB patients with type 2 diabetes without obesity. Correlation between steatosis and fibrosis and disease was analyzed.
Results: Steatosis of patients with type 2 diabetes was significantly higher compared to those of controls (p=0.042) further more patients with type 2 diabetes and obesity had higher level of steatosis than those without obesity. Also, patients with type 2 DM and obesity had higher levels of fibrosis than controls (p=0.023).
Conclusion: Diabetic patients with insulin resistance (IR) and obesity have high prevalence of NAFLD and advanced liver fibrosis and we can use fibroscan for assessment of fibrosis and steatosis in those patients.

Keywords